Skin Laboratory Public Company Limited

As of June 30, 2026, Skin Laboratory Public Company Limited carries a market capitalization of 129.60M, placing it among publicly traded companies globally. Its enterprise value stands at 73.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Skin Laboratory Public Company Limited has 144.00M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.81, and the price-to-book ratio stands at 1.50.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 73.55M versus a market cap of 129.60M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Skin Laboratory Public Company Limited maintains a current ratio of 7.68, meaning it holds 7.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.92, indicating moderate leverage, while an interest coverage ratio of -154.00 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.28M in revenue per employee across its workforce of 28.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Skin Laboratory Public Company Limited recorded an income tax benefit of -374,242.36 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -18.33M and -17.95M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Skin Laboratory Public Company Limited's stock has declined approximately 53.14% over the past 52 weeks. The 50-day moving average sits at 0.88, while the 200-day moving average is 1.05.

Over the twelve months ended June 30, 2026, Skin Laboratory Public Company Limited generated 149.04M in revenue and converted that into -17.95M in net income, yielding earnings per share of -0.13. EBITDA reached -16.47M, while operating income came in at -16.61M.

As of June 30, 2026, Skin Laboratory Public Company Limited holds 56.84M in cash and equivalents against 792,349.00 in total debt, resulting in a net debt position of -56.84M. Total book value stands at 86.49M, with working capital of 84.55M providing operational flexibility.

Skin Laboratory Public Company Limited produced -18.88M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -18.88M - equivalent to -0.14 per share.

Over the twelve months ended June 30, 2026, Skin Laboratory Public Company Limited posted a gross margin of 70.67, reflecting its pricing power and cost economics. The operating margin of -11.15 and net profit margin of -12.05 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Skin Laboratory Public Company Limited paid dividends of 0.06 per share. The dividend payout ratio of -47.35 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -15.59: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -32.40, meaning Skin Laboratory Public Company Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Skin Laboratory Public Company Limited has an Altman Z-Score of 6.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.